Related Experiment Video
Updated: Jul 12, 2025

Author Spotlight: Advancing Research on Candida albicans Biofilm-Associated Prosthetic Joint Infections
Published on: February 2, 2024
Incidence of Rifampicin Resistance in Periprosthetic Joint Infection: A Single-Centre Cohort Study on 238 Patients
Stergios Lazarinis1, Nils P Hailer1, Josef D Järhult2
1Department of Surgical Sciences, Orthopaedics, Uppsala University, SE-751 85 Uppsala, Sweden.
Background:
Rifampicin is a pillar in the treatment of periprosthetic joint infection (PJI). However, rifampicin resistance is an increasing threat to PJI treatment. This study explores the incidence of rifampicin-resistant bacteria over time in a Swedish tertiary referral centre and the association of rifampicin resistance with infection-free survival after PJI.
Methods:
The study included 238 staphylococcal PJIs treated between 2001 and 2020 for which susceptibility data for rifampicin were available. Data on causative bacteria, rifampicin resistance, treatment, and outcome were obtained. Kaplan-Meier survival analysis and Cox regression modelling estimated the infection-free cumulative survival and adjusted hazard ratios (HRs) for the risk of treatment failure.
Results:
Rifampicin-resistant causative bacteria were identified in 40 cases (17%). The proportion of rifampicin-resistant agents decreased from 24% in 2010-2015 to 12% in 2016-2020. The 2-year infection-free survival rates were 78.6% (95% CI, 66.4-93.1%) for the rifampicin-resistant group and 90.0% (95% CI, 85.8-94.4%) for the rifampicin-sensitive group. Patients with PJI caused by rifampicin-resistant bacteria had an increased risk of treatment failure (adjusted HR, 4.2; 95% CI, 1.7-10.3).
Conclusions:
The incidence of PJI caused by rifampicin-resistant bacteria did not increase over the past 20 years. The risk of treatment failure in PJI caused by rifampicin-resistant bacteria is more than four times that caused by rifampicin-sensitive bacteria, highlighting the importance of limiting the development of rifampicin resistance.
Insights
Rifampicin resistance in periprosthetic joint infections (PJI) did not increase, but resistant bacteria raise treatment failure risk over fourfold. Limiting resistance is crucial for effective PJI management.
Area of Science:
- Infectious Diseases
- Orthopedic Surgery
- Microbiology
Background:
- Rifampicin is essential for treating periprosthetic joint infection (PJI).
- Increasing rifampicin resistance poses a significant challenge to PJI treatment efficacy.
- Understanding resistance trends and outcomes is vital for optimizing PJI management.
Purpose of the Study:
- To investigate the incidence of rifampicin-resistant bacteria in PJI over two decades.
- To analyze the association between rifampicin resistance and infection-free survival in PJI patients.
- To evaluate the impact of rifampicin resistance on treatment failure rates.
Main Methods:
- Retrospective analysis of 238 staphylococcal PJI cases (2001-2020) with available rifampicin susceptibility data.
- Kaplan-Meier survival analysis to assess infection-free survival.
- Cox regression modeling to determine adjusted hazard ratios for treatment failure.
Main Results:
- Rifampicin-resistant bacteria were found in 17% of cases.
- The proportion of resistant strains decreased from 24% (2010-2015) to 12% (2016-2020).
- Patients with rifampicin-resistant PJI had a 4.2-fold increased risk of treatment failure and lower 2-year infection-free survival (78.6% vs. 90.0%).
Conclusions:
- The incidence of rifampicin-resistant PJI has not increased over the past 20 years.
- Rifampicin-resistant bacteria significantly increase the risk of treatment failure in PJI.
- Strategies to limit the development of rifampicin resistance are essential for successful PJI treatment.
Related Concept Videos
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
Acute Pyelonephritis II: Diagnostic Studies and Management
Development of Antibiotic Resistance

